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Summary Diffuse panbronchiolitis (DPB) is a distinctive form of small airway
disease, which is characterized by chronic inflammation with lymphocyte infiltration
around bronchioles. The aim of this study was to evaluate the importance of factors
related to apoptosis in peribronchiolar lymphocytes of DPB. We employed
immunohistochemical methods for the localization of Bax (a promoter of apoptosis),
Bcl-2 (an inhibitor of apoptosis), and caspase-3 (a key executioner molecule of
apoptosis) in lung tissues of five patients with DPB. In all patients, immunostaining
for Bax was almost completely absent in accumulated lymphocytes around the
bronchioles and in lymphocytes of the parafollicular area that correspond to a zone
populated by T cells. In contrast to the reaction for Bax, Bcl-2 immunoreactivity was
uniformly strong in all of the patients. The pattern of staining for caspase-3 was
similar to that for Bax in all of the patients. In normal lung tissue, a few lymphocytes
showed negative immunostaining for Bcl-2 and a positive reaction for caspase-3. Our
results suggest that Bcl-2 protein may provide T-lymphocyte survival and
hypercellularity in the bronchioles, thereby contributing to the progression of DPB.
& 2006 Elsevier Ltd. All rights reserved.
Introduction
Diffuse panbronchiolitis (DPB) is a distinctive form
of small airway disease,1 and is found almost
exclusively in Japan, with additional reports from
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China and Korea.2 The histopathologic feature of
DPB is chronic inflammation centered first on
respiratory bronchioles and surrounding alveoli
and then on distal membranous bronchioles with
mural infiltration of lymphocytes, plasma cells and
histiocytes, and intraluminal aggregates of neutro-
phils.3 In addition, bronchus-associated lymphoid
tissue (BALT) hyperplasia is frequently observed in
the lung biopsy samples from patients with DPB,4
and T-lymphocytes in bronchoalveolar lavage (BAL)
fluids obtained from patients with DPB are char-
acterized by an increased activation state, as they
express higher levels of human leukocyte antigen
(HLA)-DR than in normal subjects.5
We have previously described that long-term
macrolide antibiotics reduce the number of acti-
vated lymphocytes in BAL fluid of the patients with
DPB,5,6 and lymphocyte elimination by apoptosis is
important to terminate chronic immune response
of the murine lung to intratracheal particulate
antigen exposure.7 In this context, it has been
reported that 14-membered ring macrolide, roxi-
thromycin (RXM) augmented apoptosis in Dermato-
phagoides farinae-stimulated peripheral blood
lymphocytes (PBLs) from patients with bronchial
asthma,8 and Jun et al. also found that RXM
induced apoptosis of anti-CD3-activated Jurkat
T-lymphocytes.9 These results lead us to the
possibility that the T-lymphocytes accumulating
the airways of DPB are not apoptotic, suggesting
the persistence of airway inflammation through
their increased survival in the bronchial mucosa.
Apoptosis, a form of programmed cell death
characterized by specific morphological features, is
one of the mechanisms involved in the control of
T-lymphocytes homeostasis.10,11 The process of
apoptosis is basically mediated through two in-
dependent pathways. The first process is associated
with the cross-linking between Fas antigen and its
physiological ligand (Fas L) through the cell-to-cell
interactions.12 The second involves the mitochon-
drial-mediated apoptosis, which is partly controlled
by the family of Bcl-2 proteins. The Bcl-2 gene
family regulates the apoptotic process through the
balance of pro-apoptotic (Bax, Bcl-XS) and anti-
apoptotic products (Bcl-2, Bcl-XL).
13 Caspase-3 is
also regarded as a key executioner molecule
activated by apoptotic stimuli.14 Upregulation of
Bcl-2 proteins may cause systemic autoimmune
disease, hypersensitivity pneumonitis (HP) and
bronchial asthma through the accumulation of
activated T-lymphocytes.15–18
Having hypothesized that the accumulation of
activated lymphocytes in the lungs of DPB could
result from decreased apoptosis, the present study
was designed to evaluate the importance of factors
related to apoptosis. For this purpose, we applied
immunohistochemical staining methods to pulmon-
ary tissue from patients with DPB to evaluate the




The study group consisted of five men, ranging from
18 to 52 years of age (mean age 37712 years), in
whom the diagnosis of DPB was based on histologic
study of lung tissue by surgical lung biopsy. The
study was performed after informed consent was
obtained from the patients. Their clinical details
were described in Table 1. In brief, the patients had
no history of smoking at the time of diagnosis, and
all had chronic sinusitis. The duration of respiratory
illness, including productive cough and exertional
dyspnea was 1–12 years. All of the patients had the
decreased levels of forced expiratory volume in 1 s
(FEV1)% and PaO2 with the elevated cold hemag-
glutinin (CHA) titer. Bacteria such as Haemophilus
influenzae, Streptococcus pneumoniae, Moraxella
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Table 1 Clinical features of patients with diffuse panbronchiolitis.










1 52 Ex 12 73.3 70.1 1024 P. aeruginosa
2 18 Non 1 70.9 79.4 512 H. influenzae
P. aeruginosa
3 34 Non 5 68.7 65.2 256 H. influenzae
M. catarrhalis
4 40 Ex 5 69.4 65.6 512 S. pneumoniae
5 41 Non 6 63.9 67.7 256 H. influenzae
Ex, exsmoker; Non, nonsmoker; FEV1, forced expiratory volume in one second; CHA, cold hemagglutinin.
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catarrhalis and Pseudomonas aeruginosa were
isolated from the sputum. None had received
macrolide or corticosteroid treatment before sur-
gical lung biopsy. Histologically normal lung tissue
from lobes resected for lung cancer was used as a
control.
Immunohistochemistry of lung tissues
The expressions of Bax, Bcl-2 and caspase-3
proteins were studied on serial sections by im-
munohistochemistry. Briefly, after deparaffiniza-
tion and rehydration tissue sections (5 mm thick)
were treated with pronase for 5min (Dako Corpora-
tion, Carpinteria, CA, USA), followed by 3% hydro-
gen peroxide in methanol for 20min to inactivate
endogenous peroxidases. Lung sections were then
treated with antigen-retrieval solution (citric acid
buffer, pH 6.0) in an autoclave for 15min at 121 1C.
After washing in phosphate-buffered saline (PBS),
sections were incubated with non-specific staining
blocking reagent (Dako) for 10min, followed by
overnight incubation at 4 1C with primary mono-
clonal anti-Bcl-2 antibody (Dako) at a concentra-
tion of 1: 150 and 30min-incubation at room
temperature with polyclonal anti-Bax antibody
(Dako) at a concentration of 1:1200 or polyclonal
anti-caspase-3 antibody against the activated form
(Pharmingen, San Diego, CA, USA) at a concentra-
tion of 1:500 in a moist chamber. After three
washes with PBS, the immunoreaction product was
detected with the ENVISION system (Dako) and with
diaminobenzidine as the chromogen. The sections
were counterstained with hematoxylin. The reac-
tions obtained were graded as follows: 0, negative;
1+, weak; 2+, moderate; and 3+, strong. Omission
or replacement of the primary antibody with an
irrelevant antibody of the same species was used as
a negative control. No immunoreactivity was
observed in the negative controls.
Results
Staining for Bax
The results of immunostaining of lymphocytes in
the bronchioles are summarized in Table 2. In all of
the five patients, lymphocytes in the bronchioles
showed a negative to weak reaction for Bax, and
the staining for Bax was almost completely absent
in accumulated lymphocytes around the bronch-
ioles (Figs. 1(A) and (B)). Lymphoid follicles with
their overlying lymphoepithelium are frequently
observed in the lung biopsy samples from patients
with DPB.4 In the parafollicular area (PFA), located
in the interfollicular region, lymphocytes were
negative for Bax, while immunoreactivity for Bax
was focal and weak in the cells of the follicular area
(FA) (Figs. 2(A) and (B)). The positive immunostain-
ing for Bax was observed in alveolar macrophages
of other areas (Fig. 3(A)), and accumulated
lymphocytes in interstitium of other areas showed
negative reaction for Bax (Fig. 3(C)). In normal lung
tissue, alveolar macrophages showed intense im-
munoreactivity for Bax. Normal lymphocytes, even
if a small number of lymphocytes was observed,
were moderately positive for Bax (data not shown).
Staining for Bcl-2
In contrast to the reaction for Bax, immunostaining
for Bcl-2 was homogenously present in lymphocytes
around the bronchioles (Figs. 1(C) and (D)).
Furthermore, Bcl-2 immunoreactivity was uni-
formly strong in the lymphocytes of the PFA, while
the cells in the FA were negative for Bcl-2 (Figs.
2(C) and (D)). Alveolar macrophages in airspace of
other areas was negative for Bcl-2 immunostaining
(Fig. 3(B)) in contrast to the positive staining in
accumulated lymphocytes of interstitium of other
areas (Fig. 3(D)). Staining for Bcl-2 in the cytoplasm
of lymphocytes was moderate to strong in all of the
patients (Table 2). In normal lung tissue, alveolar
macrophages or a few lymphocytes showed weak or
negative immunostaining for Bcl-2, respectively
(data not shown).
Staining for caspase-3
In most lymphocytes around the bronchioles and in
interstitium of other areas no immunoreaction for
caspase-3 was observed (Figs. 1(E), (F) and 3(E)).
The majority of lymphocytes in the PFA also showed
negative immunostaining for caspase-3 (Figs. 2(E)
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Table 2 Summary of results of immunohisto-
chemical staining of lymphocytes around the
bronchioles.
Patient no. Bax Bcl-2 Caspase 3
1 0–1+ 3+ 0–1+
2 0 2+ to 3+ 0
3 0 2+ to 3+ 0
4 0–1+ 3+ 0–1+
5 0–1+ 2+ 0–1+
Results were similar in all patients. Staining reactions
were rated as 0, negative; 1+, weak; 2+, moderate; 3+,
strong.
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and (F)). The patterns of staining for caspase-3 and
Bax were similar in all of the patients (Table 2). In
contrast, the staining for caspase-3 was weak in the
cells of the FA and more intense in airway epithelial
cells (Figs. 2(E) and (F)). In normal lung tissue, a
few lymphocytes showed a positive reaction for
caspase-3. Alveolar macrophages also showed
moderate staining (data not shown).
Discussion
Apoptosis contributes to elimination of lung lym-
phocytes during physiologic pulmonary immune
responses to intratracheal challenge with T cell-
dependent particulate antigen in mice.7 Failure to
undergo apoptosis of T cells may therefore con-
tribute to the development of bronchial asthma.
Specimens taken from asthmatic patients have an
increased infiltration of cells expressing Bcl-2, and
the correlation between the number of the cells
expressing Bcl-2 and T-lymphocytes suggests that
Bcl-2 may be involved in the enhancement of T-cell
survival in the airways of asthmatic subjects.19 Our
results also demonstrated the involvement of Bcl-2
family proteins in the regulation of lymphocytes
susceptibility to cell death in DPB. Lymphocytes
expressing Bcl-2 but not Bax were localized
predominantly around the bronchioles and in the
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Figure 1 Immunostaining for Bcl-2 family proteins and caspase-3 in diffuse panbronchiolitis (Case 4). (A, B) The
reaction for Bax (A,  40; B,  200). (C, D) Immunostaining for Bcl-2 (C,  40; D,  200). Immunostaining for caspase-3
(E,  40; F,  200). Br, bronchiole; Ep, epithelium; Ly, lymphocytes.
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PFA that correspond to a zone populated by T cells,
as previously reported by Sato et al.,4 although
they were not clearly identified as B or T cells by
monoclonal antibody in our study. In their respec-
tive role as antagonists or promoters of apoptosis,
cellular concentrations of Bcl-2 or Bcl-XL and Bax or
Bad are normally at a state of equilibrium that
prevents activation of the cell death program.20 It
has been shown that the ratio of Bcl-2 to Bax
determines the relative amounts of Bcl-2/Bax
heterodimers and Bax/Bax homodimers; the for-
mation of these dimers provides a mechanism for
regulating the susceptibility to apoptosis.21,22 The
ligation of Fas/FasL is a cell-to-cell interaction
often implicated in the initiation of apoptosis, and
the possibility of a failure in the initiation of the
apoptosis by the Fas/FasL cannot be eliminated in
this study. Nevertheless, an overexpression of the
Bcl-2 protein in lymphocytes in culture inhibits the
Fas-induced apoptosis.23 According to this concept,
T-lymphocytes with low Bax/Bcl-2 expression ratio
in the airways of DPB patients are more resistant to
apoptotic stimuli than a similar cell type with
comparatively high ratio in those of normal
subjects. However, other apoptotic markers (ex-
pression of Fas/FasL) or techniques to assess the
apoptotic/antiapoptotic balance would have been
helpful to confirm our data, and the apoptotic/
antiapoptotic balance in other cells collected
around bronchioles and in the bronchiolar lumen
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Figure 2 Immunostaining for Bcl-2 family proteins and caspase-3 in diffuse panbronchiolitis (Case 1). (A, B) The
reaction for Bax (A,  40; B,  200). (C, D) Immunostaining for Bcl-2 (C,  40; D,  200). (E, F) Immunostaining for
caspase-3 (E,  40; F,  200). PFA, parafollicular area; FA, follicular area; Ep, epithelium.
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could also increase the value of the study. In
addition, our data which are presented in a
semiquantitative mode would be more appropri-
ately depicted with a morphometric analysis, if
tissue specimens of DPB had been more available.
Caspase-3 is finally activated to execute apopto-
sis by apoptotic stimuli originating either at
receptors for exogenous molecules or within cells
through the action of drugs, toxins, or radia-
tion.14,24–26 The present study demonstrated the
reduced expression of caspase-3 in lymphocytes of
the parafollicular area, which is thought to involve
impairments of T-lymphocyte apoptosis. Collec-
tively, we suggests that Bcl-2 protein may play a
role in the pathogenesis of DPB by providing a
survival advantage that allows potentially patho-
genic, activated T-lymphocytes to perpetuate a
continuous cycle of inflammation and tissue de-
struction within the intrabronchiolar compartment.
The follicular area in DPB manifests the char-
acteristics of a B cell zone, which appears to be the
equivalent of the germinal center of the peripheral
lymph nodes.4 Our study showed that follicular area
cells expressed caspase-3, in contrast to the lack of
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Figure 3 Immunostaining for Bcl-2 family proteins and caspase-3 in diffuse panbronchiolitis (Case 2). (A, C) The
reaction for Bax ( 200). (B, D) Immunostaining for Bcl-2 ( 200). E, Immunostaining for caspase-3 ( 200). AM,
alveolar macrophages; Ly, lymphocytes.
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Bcl-2 protein, which is associated with the induc-
tion of apoptosis. This result is consistent with a
previous report27 which showed that most germinal
center cells of the peripheral lymph nodes lack Bcl-
2 protein and upregulate expression of Fas antigen,
which may be related to the induction of apoptosis.
Therefore, Bcl-2 downregulation plays an impor-
tant role in the apoptotic events in the follicular
area cells in DPB as well as in germinal center cells
in the peripheral lymph nodes.
We have previously described that long-term
macrolide antibiotics reduce the number of acti-
vated T-lymphocytes in BAL fluid of the patients
with DPB,5,6 and this may account for its clinical
effectiveness in the treatment of the disease.28,29
The antiinflammatory activity of the drugs have
been reported to be the action on lymphocyte
apoptosis.8,9,30 RXM aurguments the apoptosis in D.
farinae-stimulated PBLs from asthma patients8 and
induces apoptosis of anti-CD3-activated Jurkat
T-lymphocytes.9 Our recent study also demon-
strated that clarithromycin and azithromycin in-
duce the apoptosis in anti-CD3/CD28-activated
PBLs obtained from normal subjects through the
downregulation of an anti-apoptotic product, Bcl-
XL.
30 Taken together, these findings support the
hypothesis that macrolides reduce the presence of
activated T-lymphocytes at the site of inflammation
by promoting T-cell apoptosis via the downregula-
tion of anti-apoptotic Bcl-2 protein family in DPB.
In conclusion, we have presented evidence that
intrabronchiolar T-lymphocytes from DPB patients
express a high level of anti-apoptotic protein, Bcl-2.
It may promote T-lymphocyte survival and hyper-
cellularity, thereby contributing to the progression
of the disease. These data may have implications
for the design of more targeted therapeutic
strategies in DPB.
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